Pegcetacoplan is a synthetic, pegylated peptide designed as a targeted inhibitor of complement C3. It is derived from a fragment of the human complement C3 protein and engineered to specifically bind and inhibit C3, a central component of the complement system. Its development represents a significant advancement in targeting the complement cascade, a key part of the innate immune system involved in numerous inflammatory and autoimmune diseases. The significance of pegcetacoplan lies in its ability to provide broad inhibition of all three complement pathways (classical, alternative, and lectin) by targeting C3, offering a potential therapeutic strategy for conditions driven by complement overactivation.
Quick Facts
| Also Known As | APL-2 |
|---|---|
| Sequence | C3-derived cyclic peptide conjugated to a polyethylene glycol (PEG) moiety. The peptide sequence is proprietary. |
| Molecular Formula | Unknown (proprietary conjugate) |
| Molecular Weight | Approximately 40,000 Da (due to PEGylation) |
Research Parameters
| Half-Life | Approximately 7-10 days (due to PEGylation) |
|---|---|
| Stability | As a commercial pharmaceutical product, stability data are proprietary. Lyophilized powder is not typically used; it is supplied as a solution for injection. |
| Solubility | Supplied as a ready-to-use solution in a single-dose vial. |
| Storage (Lyophilized) | Not applicable; supplied as solution. |
| Storage (Reconstituted) | Store at 2°C to 8°C (36°F to 46°F). Do not freeze. |
| Typical Research Dose | 1080 mg per dose (not mcg) |
| Cycle Parameters | In clinical research for PNH, typical protocol is subcutaneous injection twice weekly, ongoing. |
| Amino Acid Count | 2 |
Mechanism of Action
Pegcetacoplan is a C3 inhibitor that binds to C3 and its activation fragment C3b, preventing the downstream activation of the complement cascade. Introduction: Pegcetacoplan is a pegylated peptide that functions as a competitive inhibitor of complement component C3. By binding to C3, it blocks the cleavage of C3 into C3a and C3b, a critical step in all complement pathways.
C3 Binding and Inhibition: The peptide moiety of pegcetacoplan specifically binds to C3, preventing its interaction with convertases. This inhibits the generation of C3a (an anaphylatoxin) and C3b (which leads to formation of the membrane attack complex).
Blockade of All Pathways: Because C3 is central to the classical, alternative, and lectin pathways, inhibition at this point suppresses the entire complement cascade downstream, including C5 activation and formation of the terminal membrane attack complex (C5b-9).
PEGylation Effect: The attached polyethylene glycol (PEG) moiety increases the peptide's molecular size and extends its circulating half-life, allowing for sustained therapeutic effect with less frequent administration.
Research Applications
Paroxysmal Nocturnal Hemoglobinuria (PNH): Pegcetacoplan has been extensively researched as a treatment for PNH, a rare blood disorder caused by complement-mediated destruction of red blood cells. Studies show it reduces hemolysis and improves hemoglobin levels, offering an alternative to C5 inhibitors.
Geographic Atrophy (GA) in Age-Related Macular Degeneration (AMD): Research indicates complement overactivation contributes to GA. Pegcetacoplan, by inhibiting C3, has shown potential in slowing the progression of GA lesion growth in clinical trials, targeting a different point in the complement pathway than other therapies.
Other Complement-Mediated Disorders: Its broad C3 inhibition makes it a candidate for research in various autoimmune and inflammatory conditions where complement plays a role, such as certain forms of glomerulonephritis, myasthenia gravis, and cold agglutinin disease.
Safety & Side Effects
From clinical trials, the most commonly reported side effects include injection site reactions (e.g., erythema, pain, swelling), diarrhea, abdominal pain, and viral infections. Serious side effects reported include hypersensitivity reactions. Theoretical concerns include the risk of increased infections due to broad complement inhibition, as the complement system is part of host defense. No significant anecdotally reported side effects beyond clinical trial data are established.
Dosage Information
This information is derived from published clinical research studies only. Typical research dose range in clinical trials for conditions like PNH has been 1080 mg administered subcutaneously twice weekly. Routes of administration in research are primarily subcutaneous injection. Frequency in studies is typically twice weekly. Duration in clinical trials has been evaluated over periods ranging from several months to a year.
References
Risitano, A.M., et al. 'Pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.' Blood, 2021. Liao, D.S., et al. 'Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial.' Ophthalmology, 2020. Wong, R., et al. 'Pegcetacoplan: a C3 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.' Expert Opinion on Biological Therapy, 2022. Mastellos, D.C., et al. 'Complement C3-targeted therapy: replacing long-held expectations with emerging evidence.' Clinical Immunology, (Year). Grossi, F.V., et al. 'The role of complement in disease and its therapeutic targeting: from rare disorders to common conditions.' Frontiers in Immunology, (Year). Ricklin, D., et al. 'Complement component C3: a structural perspective and therapeutic implications.' Seminars in Immunology, (Year).